JP2022533939A5 - - Google Patents

Info

Publication number
JP2022533939A5
JP2022533939A5 JP2021567059A JP2021567059A JP2022533939A5 JP 2022533939 A5 JP2022533939 A5 JP 2022533939A5 JP 2021567059 A JP2021567059 A JP 2021567059A JP 2021567059 A JP2021567059 A JP 2021567059A JP 2022533939 A5 JP2022533939 A5 JP 2022533939A5
Authority
JP
Japan
Prior art keywords
solvate
pharmaceutically acceptable
acceptable salt
compound according
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021567059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533939A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032939 external-priority patent/WO2020236524A1/en
Publication of JP2022533939A publication Critical patent/JP2022533939A/ja
Publication of JP2022533939A5 publication Critical patent/JP2022533939A5/ja
Pending legal-status Critical Current

Links

JP2021567059A 2019-05-17 2020-05-14 線維芽細胞増殖因子受容体キナーゼの阻害剤 Pending JP2022533939A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962849534P 2019-05-17 2019-05-17
US62/849,534 2019-05-17
US201962907491P 2019-09-27 2019-09-27
US62/907,491 2019-09-27
PCT/US2020/032939 WO2020236524A1 (en) 2019-05-17 2020-05-14 Inhibitors of fibroblast growth factor receptor kinases

Publications (2)

Publication Number Publication Date
JP2022533939A JP2022533939A (ja) 2022-07-27
JP2022533939A5 true JP2022533939A5 (enExample) 2023-05-08

Family

ID=73458745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021567059A Pending JP2022533939A (ja) 2019-05-17 2020-05-14 線維芽細胞増殖因子受容体キナーゼの阻害剤

Country Status (7)

Country Link
US (1) US20230174535A1 (enExample)
EP (1) EP3969442A4 (enExample)
JP (1) JP2022533939A (enExample)
CN (1) CN114127051A (enExample)
AU (1) AU2020278566A1 (enExample)
CA (1) CA3139161A1 (enExample)
WO (1) WO2020236524A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US11345681B1 (en) * 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN116096707A (zh) * 2020-06-05 2023-05-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂
KR20240119095A (ko) * 2021-12-08 2024-08-06 킨네이트 바이오파마 인크. Fgfr 저해제의 고체 상태 형태
WO2023107870A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN120344533A (zh) * 2022-11-22 2025-07-18 海思科医药集团股份有限公司 一种嘧啶衍生物及其在医药上的应用
AU2024301095A1 (en) * 2023-07-26 2026-03-12 Khora Spv 1, Llc Treatment of cancer with a cdk inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168968B1 (en) * 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007064931A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY171055A (en) * 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
GB201503590D0 (en) * 2015-03-03 2015-04-15 Davis Adrian Topical formulation
PT3279202T (pt) * 2015-03-31 2020-08-31 Taiho Pharmaceutical Co Ltd Cristal de composto de alquinilo de benzeno 3,5-dissubstituído
US11221750B2 (en) * 2016-02-12 2022-01-11 Purdue Research Foundation Manipulating 3D virtual objects using hand-held controllers
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
US10685111B2 (en) * 2016-10-31 2020-06-16 Crowdstrike, Inc. File-modifying malware detection
US11130761B2 (en) * 2016-12-29 2021-09-28 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors

Similar Documents

Publication Publication Date Title
JP2022533939A5 (enExample)
JP2024050527A5 (enExample)
JP2024520481A5 (enExample)
JP2023531269A5 (enExample)
JP2024514837A5 (enExample)
JP2022543767A5 (enExample)
JP2019529490A5 (enExample)
JP2011519854A5 (enExample)
JP2017528498A5 (enExample)
JP2005535586A5 (enExample)
JP2008528447A5 (enExample)
JP2019517487A5 (enExample)
JP2018531218A5 (enExample)
RU2010136665A (ru) Новые пиридиноны и пиридазиноны
JP2020502047A5 (enExample)
JP2011509309A5 (enExample)
JP2013542267A5 (enExample)
JP2020535165A5 (enExample)
JP2020534264A5 (enExample)
JP2024532768A5 (enExample)
JP2024516033A5 (enExample)
JP2025502943A5 (enExample)
JP2023520396A5 (enExample)
JP2024545787A5 (enExample)
JP2023553428A5 (enExample)